A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Disease-free survival
Approximately 37 months
No
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
GO27826
NCT01667419
December 2012
May 2020
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
Louisville, Kentucky 40207 | |
Hackensack, New Jersey 07601 | |
Denver, Colorado | |
Charlotte, North Carolina | |
Eugene, Oregon | |
Indianapolis, Indiana | |
Charleston, South Carolina | |
Charleston, West Virginia 25304 | |
Coeur D'alene, Idaho 83814 |